Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.7190
+0.02483.57%
Post-market: 0.72680.0078+1.08%19:19 EDT
Volume:261.48K
Turnover:184.09K
Market Cap:16.09M
PE:-0.29
High:0.7199
Open:0.7025
Low:0.6850
Close:0.6942
52wk High:2.48
52wk Low:0.6300
Shares:22.38M
Float Shares:18.81M
Volume Ratio:0.68
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4637
EPS(LYR):-3.3830
ROE:-47.85%
ROA:-17.68%
PB:0.20
PE(LYR):-0.21

Loading ...

Citius Oncology posts FY cash balance of USD 3.9 million and accumulated deficit of USD 64.0 million

Reuters
·
Dec 24, 2025

Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering

Reuters
·
Dec 11, 2025

Citius Oncology Sells Shares and Warrants in $18 Million Private Placement

Reuters
·
Dec 09, 2025

Citius Oncology Inc - Proceeds Support Launch of Lymphir for Cutaneous T-Cell Lymphoma

THOMSON REUTERS
·
Dec 09, 2025

Citius Oncology Inc - to Purchase 1,284,404 Shares of Common Stock at $1.09 per Share in Direct Offering

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries

Reuters
·
Dec 04, 2025

Citius Oncology Expands Lymphir™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement With Er-Kim

THOMSON REUTERS
·
Dec 04, 2025

Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

Reuters
·
Dec 02, 2025

Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)

THOMSON REUTERS
·
Dec 02, 2025

Citius Oncology Showcases LYMPHIR at American Society of Hematology Annual Meeting

Reuters
·
Nov 25, 2025

Citius Oncology to advance launch of Lymphir with Verix AI integration

TIPRANKS
·
Nov 21, 2025

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Oct 22, 2025

BRIEF-Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Reuters
·
Oct 21, 2025

BRIEF-Citius Oncology Signs U.S. Distribution Agreement With Mckesson To Support Lymphir Commercial Launch

Reuters
·
Oct 20, 2025

Citius Oncology announces distribution agreement with McKesson

TIPRANKS
·
Oct 20, 2025

Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4

MT Newswires Live
·
Oct 16, 2025

BRIEF-Citius Oncology Signs Exclusive Commercialization Agreement With EVERSANA To Support Planned Q4 2025 Launch Of LYMPHIR

Reuters
·
Oct 16, 2025

Citius Oncology Inc: Co Plans to Commercially Launch Lymphir in United States in Q4 2025

THOMSON REUTERS
·
Oct 16, 2025

Citius Oncology Signs Exclusive Commercialization Agreement With Eversana to Support Planned Q4 2025 Launch of Lymphir™

THOMSON REUTERS
·
Oct 16, 2025